NASDAQ:AXSM | Free Cash Flow | Axsome Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2014-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$20.7M$121,000.00-$20.82M
2025-12-31-$18.65M$71,000.00-$18.72M
2025-03-31-$43.38M$338,000.00-$43.71M
2024-12-31-$26.2M$30,000.00-$26.23M
2024-03-31-$53.47M$98,000.00-$53.57M
2023-12-31-$30.36M$7,000.00-$30.37M
2023-03-31-$5.82M$71,000.00-$5.89M
2022-12-31-$27.56M$181,000.00-$27.74M
2022-03-31-$32.65M$214,000.00-$32.87M
2021-12-31-$28.84M$451.00-$28.84M
2021-03-31-$27.22M$29,995.00-$27.25M
2020-12-31-$20.55M$20,287.00-$20.57M
2020-03-31-$23.27M$9,331.00-$23.28M
2019-12-31-$17.57M$1,461.00-$17.57M
2019-03-31-$9.5M
2018-12-31-$9.79M$0.00-$9.79M
2018-03-31-$6.68M$14,576.00-$6.7M
2017-12-31-$6.29M$1.00-$6.29M
2017-03-31-$6.64M$2,899.00-$6.64M
2016-12-31-$7.22M$6,055.00-$7.22M
2016-03-31-$3.95M$10,651.00-$3.96M
2015-12-31-$2.25M$4,112.00-$2.25M
2015-03-31-$1.16M$10,256.00-$1.17M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$93.41M$480,000.00-$93.89M
2024-12-31-$128.41M$270,000.00-$128.68M
2023-12-31-$145.08M$582,000.00-$145.66M
2022-12-31-$116.51M$702,000.00-$117.21M
2021-12-31-$108.23M$308,000.00-$108.53M
2020-12-31-$78.46M$45,891.00-$78.5M
2019-12-31-$46.38M$16,121.00-$46.39M
2018-12-31-$30.05M$32,696.00-$30.09M
2017-12-31-$26.47M$9,898.00-$26.48M
2016-12-31-$21.28M$104,561.00-$21.39M
2015-12-31-$7.44M$20,195.00-$7.46M
2014-12-31-$4.6M